Clinical Research Directory
Browse clinical research sites, groups, and studies.
Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants
Sponsor: Alexion Pharmaceuticals, Inc.
Summary
This is a 2-part, open label, fixed-sequence study to evaluate the potential drug interaction between ALXN2050 and fluconazole (Part 1), and between ALXN2050 and rifampin (Part 2) in healthy adult participants. Part 1 will be a 2-period, fixed-sequence study. Part 2 will be a single-period, fixed-sequence study.
Official title: A Phase 1 Two-Part Study to Evaluate the Potential Drug Interactions Between ALXN2050 and Fluconazole, and Between ALXN2050 and Rifampin in Healthy Adult Participants
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
16
Start Date
2021-06-07
Completion Date
2021-08-23
Last Updated
2026-07-16
Healthy Volunteers
Yes
Conditions
Interventions
ALXN2050
Oral tablet.
Fluconazole
Oral tablet.
Rifampin
Oral capsule.
Locations (1)
Clinical Trial Site
Tempe, Arizona, United States